一种用于克服非小细胞肺癌治疗中抗原异质性的多靶向 CAR-T 细胞平台
A Multi-Targeting Chimeric Antigen Receptor-T Cell Platform to Overcome Antigen Heterogeneity in the Treatment of Non-Small Cell Lung Cancer.
这些发现支持采用多靶点CAR-T 策略来应对NSCLC及可能其他实体瘤中的抗原异质性。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:CD81 and CD82 expressing tumor-infiltrating lymphocytes in the NSCLC tumor microenvironment play a crucial role in T-cell activation and cytokine production.
CD81 and CD82 expressing tumor-infiltrating lymphocytes in the NSCLC tumor microenvironment play a crucial role in T-cell activation and cytokine production.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
这些发现凸显了 CD81 和 CD82 在 T 细胞活化、细胞因子产生、记忆亚群积累以及靶细胞裂解中的多重作用。因此,这些发现表明 CD81 和 CD82 有潜力作为共刺激分子的候选者,用于复杂 TME 内癌症治疗的免疫治疗策略。
为了理解非小细胞肺癌(NSCLC)肿瘤微环境(TME)中的免疫系统,阐明与T细胞活化相关的分子特征至关重要。
我们利用从19例NSCLC患者组织样本中获得的单细胞RNA测序数据进行了深入分析。根据肿瘤区域内的肿瘤比例评分(TPS)对T细胞进行分类,并分析了高TPS区域T细胞中与活化和耗竭相关的分子标志物。
值得注意的是,属于tetraspanin蛋白家族的tetraspanins CD81和CD82被发现表达于活化的T细胞,尤其是细胞毒性T细胞。这些tetraspanins与活化标志物和耗竭标志物表现出强相关性。体外实验证实,IL-2刺激的T细胞中CD81和CD82表达增加。根据表达水平将T细胞分为CD81 high CD82 high和CD81 low CD82 low组,与CD81 low CD82 low T细胞相比,CD81 high CD82 high T细胞表现出更高的活化标志物如CD25和CD69。这一趋势在CD3 +、CD8 + 和CD4 + T细胞亚群中一致。此外,CD81 high CD82 high T细胞在抗CD3刺激下,表现出IFN-γ、TNF-α和IL-2等细胞因子分泌增强,同时记忆T细胞比例增加。分选CD81 high CD82 high和CD81 low CD82 low T细胞后的bulk RNA测序结果一致支持CD81和CD82的作用。过表达CD81和CD82的实验显示对靶细胞的细胞毒性增加。
We conducted an in-depth analysis using single-cell RNA sequencing data obtained from tissue samples of 19 NSCLC patients. T cells were classified based on the Tumor Proportion Score (TPS) within the tumor region, and molecular markers associated with activation and exhaustion were analyzed in T cells from high TPS areas.
Notably, tetraspanins CD81 and CD82, belonging to the tetraspanin protein family, were found to be expressed in activated T cells, particularly in cytotoxic T cells. These tetraspanins showed strong correlations with activation and exhaustion markers. In vitro experiments confirmed increased expression of CD81 and CD82 in IL-2-stimulated T cells. T cells were categorized into CD81 high CD82 high and CD81 low CD82 low groups based on their expression levels, with CD81 high CD82 high T cells exhibiting elevated activation markers such as CD25 and CD69 compared to CD81 low CD82 low T cells. This trend was consistent across CD3 + , CD8 + , and CD4 + T cell subsets. Moreover, CD81 high CD82 high T cells, when stimulated with anti-CD3, demonstrated enhanced secretion of cytokines such as IFN-γ, TNF-α, and IL-2, along with an increase in the proportion of memory T cells. Bulk RNA sequencing results after sorting CD81 high CD82 high and CD81 low CD82 low T cells consistently supported the roles of CD81 and CD82. Experiments with overexpressed CD81 and CD82 showed increased cytotoxicity against target cells. DISCUSSION: These findings highlight the multifaceted roles of CD81 and CD82 in T cell activation, cytokine production, memory subset accumulation, and target cell cytolysis. Therefore, these findings suggest the potential of CD81 and CD82 as promising candidates for co-stimulatory molecules in immune therapeutic strategies for cancer treatment within the intricate TME.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。